UCB Promotes 'Underappreciated' Pipeline In FY Results
Executive Summary
UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and unmet needs in neurodegenerative diseases like Alzheimer's.
You may also be interested in...
UCB's Bimekizumab Could Struggle With Saturated Psoriasis Market
UCB's has reported strong Phase IIb data for its novel psoriasis therapy bimekizumab, but the drug is unlikely to launch before 2022 and is at risk of being redundant on a crowded market.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.